Who Can Take Olaparib: — Eligibility by Gene Test and Cancer Type

In most cases, a negative BRCA result means olaparib is not indicated. The main exception is prostate cancer, where mutations in other HRR genes — beyond BRCA alone — can also qualify. If you have prostate cancer and your test covered only BRCA, ask your oncologist whether a broader HRR gene panel was included. For ovarian, breast and pancreatic cancer, a negative BRCA result generally rules olaparib out, and your oncologist will explain which treatment options remain appropriate for your situation.

A blood test detects mutations present in every cell of your body — ones inherited from a parent. If positive, your close blood relatives may carry the same mutation. A tumour tissue test looks only at the cancer cells and can detect mutations that developed in the tumour itself without being inherited. Both types of mutation can qualify you for olaparib. Your oncologist will advise which test is right for your situation; sometimes both are done.

If your result is germline — found by a blood test, meaning it was inherited — close relatives such as parents, siblings and children may want to consider genetic counselling and testing. This does not mean they have cancer, but a confirmed BRCA mutation raises the risk of certain cancers, and there are surveillance and risk-reduction options available to carriers. If your result is somatic — found only in the tumour tissue — it was not inherited and your relatives do not need testing for this reason.

Turnaround time varies by laboratory and whether the sample needs to go to a specialist reference centre. A germline BRCA blood test typically takes one to three weeks. A somatic tumour tissue test can take a similar amount of time, depending on the quality and quantity of tissue available from your biopsy. If the original sample is insufficient, a repeat biopsy may be needed before testing can proceed. Ask your team when the sample was sent and when to expect the result, so you are not waiting without a timeline.

Yes. Olaparib has received approval from CDSCO, India's central drug regulator, for eligible patients in approved indications. It is taken as an oral tablet at home twice daily, so it does not require an infusion visit. Cost is a significant practical consideration; ask your oncologist about current pricing, any available patient access programmes, and whether your health insurance covers it. Any cost figure you find online is likely to be outdated — always confirm pricing directly with the dispensing pharmacy or your treating centre at the time of prescription.

Not being eligible does not mean you are out of treatment options — it means a different treatment fits your cancer's biology better. Your oncologist will discuss alternatives suited to your cancer type and stage, which may include chemotherapy, other targeted therapies, hormonal treatment, or a clinical trial. It is reasonable to ask two specific questions: why was olaparib ruled out, and what is the recommended alternative expected to achieve. Leaving the appointment with clear answers to both helps you and your family plan ahead.